What is Theravance Biopharma's AOCI?

Theravance Biopharma (TBPH) reported AOCI of -$62K in Q1 2026.

What is the long-term trend for Theravance Biopharma's AOCI?

Over 4 years (2020 to 2025), Theravance Biopharma's AOCI has grown at a 6.7% compound annual growth rate (CAGR), from $47K to $61K.

Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.

Theravance Biopharma TBPH AOCI

AOCI at other companies

Zevra Therapeutics, Inc.ZVRA

-$1.8M-2,091%

United TherapeuticsUTHR

-$10.2M-750%

Aurinia PharmaceuticalsAUPH

-$880K-6.7%

PrecigenPGEN

-$17K-242%

Ultragenyx PharmaceuticalRARE

$0+100%

OrganonOGN

-$539M+12.6%

Other financials

Income statement

See full

Revenue$17.7M+15.0%

Operating income-$9.5M+34.3%

Net income-$4.9M+63.7%

EPS (diluted)-$0.10+63.0%

Balance sheet

See full

Cash & equivalents$288.1M+160%

Total debt$40.5M-15.9%

Total equity$290.6M+75.1%

Total assets$472.3M+37.5%

Cash flow

See full

Operating cash flow$73.3M+70.3%

CapEx$8.0K-95.8%

Free cash flow$59.6M+5,560%

Valuation

See full

Market cap$890.32M+67.5%

Enterprise value$642.72M+37.0%

P/E7.8×—

P/S8.1×0.0×

Profitability

See full

Gross margin60.8%—

Operating margin1.2%+0.6pp

Net margin104.3%+71.4pp

FCF margin221.9%+206pp

Returns & leverage

See full

Return on equity50.2%+36.2pp

Debt / equity0.1×-0.2×

Current ratio13.1×+8.4×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Theravance Biopharma's AOCI?: Theravance Biopharma (TBPH) reported AOCI of -$62K in Q1 2026.
What is the long-term trend for Theravance Biopharma's AOCI?: Over 4 years (2020 to 2025), Theravance Biopharma's AOCI has grown at a 6.7% compound annual growth rate (CAGR), from $47K to $61K.
What does AOCI mean?: Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.